(RS)-tegafur
Sign in to saveAlso known as MJF-12264, 1-(2-tetrahydrofuryl)-5-fluorouracil, tegafur
Tegafur is a chemotherapeutic prodrug of 5-fluorouracil (5-FU) used in the treatment of cancers. It is a component of the combination drug tegafur/uracil. When metabolised, it becomes 5-FU.
Research
21 papers- Efficacy and safety of RS plus bevacizumab versus RS plus fruquintinib as the third-line therapy in patients with refractory metastatic colorectal cancer: A real-world propensity score matching study.Journal of evidence-based medicine · 2024
- The pharmacology of ftorafur (R, S-1-(tetrahydro-2-furanyl)-5-fluorouracil.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 1981
- Effect of CYP2A6 genetic polymorphism on the metabolic conversion of tegafur to 5-fluorouracil and its enantioselectivity.Drug metabolism and disposition: the biological fate of chemicals · 2014
- Stereoselective metabolism of ftorafur (R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil).Cancer chemotherapy and pharmacology · 1981
- Real‑world treatment outcomes among patients with metastatic pancreatic cancer in Japan: The Tokushukai real‑world data project.Molecular and clinical oncology · 2023
via PubMed
~2 min read
Encyclopedic overview
8 sectionsContents
- Medical uses
- Adverse effects
- Pharmacogenetics
- Mechanism of action
- Pharmacokinetics
- Interactive pathway map
- See also
- References
Tegafur is a chemotherapeutic prodrug of 5-fluorouracil (5-FU) used in the treatment of cancers. It is a component of the combination drug tegafur/uracil. When metabolised, it becomes 5-FU.
It was patented in 1967 and approved for medical use in 1972.
Excerpted from Wikipedia’s “(RS)-tegafur” article, available under the CC BY-SA 4.0 licence.
Available in 14 languages
- Français
- Deutsch
- 日本語
- Русский
- Português
- Italiano
- Bahasa Indonesia
- Latvian
- Romanian
- Serbian
- Serbian (Latin)
- Tiếng Việt
- Ukrainian
via Wikidata sitelinks · CC0